4.7 Article

Role of Transmitted Gag CTL Polymorphisms in Defining Replicative Capacity and Early HIV-1 Pathogenesis

期刊

PLOS PATHOGENS
卷 8, 期 11, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.ppat.1003041

关键词

-

资金

  1. International AIDS Vaccine Initiative
  2. Virology Core at the Emory Center for AIDS Research [P30 AI050409]
  3. Action Cycling Fellowships
  4. Yerkes National Primate Research Center base grant [2P51RR000165-51]
  5. National Center for Research Resources [P51RR165]
  6. Office of Research Infrastructure Programs [OD P51OD11132]
  7. [R01 AI64060]
  8. [R37 AI51231]

向作者/读者索取更多资源

Initial studies of 88 transmission pairs in the Zambia Emory HIV Research Project cohort demonstrated that the number of transmitted HLA-B associated polymorphisms in Gag, but not Nef, was negatively correlated to set point viral load (VL) in the newly infected partners. These results suggested that accumulation of CTL escape mutations in Gag might attenuate viral replication and provide a clinical benefit during early stages of infection. Using a novel approach, we have cloned gag sequences isolated from the earliest seroconversion plasma sample from the acutely infected recipient of 149 epidemiologically linked Zambian transmission pairs into a primary isolate, subtype C proviral vector, MJ4. We determined the replicative capacity (RC) of these Gag-MJ4 chimeras by infecting the GXR25 cell line and quantifying virion production in supernatants via a radiolabeled reverse transcriptase assay. We observed a statistically significant positive correlation between RC conferred by the transmitted Gag sequence and set point VL in newly infected individuals (p = 0.02). Furthermore, the RC of Gag-MJ4 chimeras also correlated with the VL of chronically infected donors near the estimated date of infection (p = 0.01), demonstrating that virus replication contributes to VL in both acute and chronic infection. These studies also allowed for the elucidation of novel sites in Gag associated with changes in RC, where rare mutations had the greatest effect on fitness. Although we observed both advantageous and deleterious rare mutations, the latter could point to vulnerable targets in the HIV-1 genome. Importantly, RC correlated significantly (p = 0.029) with the rate of CD4+ T cell decline over the first 3 years of infection in a manner that is partially independent of VL, suggesting that the replication capacity of HIV-1 during the earliest stages of infection is a determinant of pathogenesis beyond what might be expected based on set point VL alone.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Orthopedics

Does Aseptic Revision Risk Differ for Primary Total Knee Arthroplasty Patients Who Have and Do not Have a Prior Primary or Revision Arthroplasty?

Heather A. Prentice, Priscilla H. Chan, Nithin C. Reddy, Ronald A. Navarro, Robert S. Namba, Elizabeth W. Paxton

Summary: The study aimed to assess the risk of aseptic revision in total knee arthroplasty (TKA) patients with and without a history of primary or revision arthroplasty of a different major joint. A matched cohort study was conducted using data from Kaiser Permanente's arthroplasty registries. The results showed that patients without a history of prior aseptic revision in a different joint had a higher risk of aseptic revision in the index knee, while no difference in aseptic revision risk was observed for patients with a history of primary arthroplasty in a different joint. Patients with a history of revision had over a 2-fold higher risk of aseptic revision in the index knee, emphasizing the need for close surveillance of these patients.

JOURNAL OF ARTHROPLASTY (2023)

Article Clinical Neurology

Trans-Synaptic Degeneration Following Acute Optic Neuritis in Multiple Sclerosis

Olwen C. Murphy, Elias S. Sotirchos, Grigorios Kalaitzidis, Elena Vasileiou, Henrik Ehrhardt, Jeffrey Lambe, Ohemaa Kwakyi, James Nguyen, Alexandra Zambriczki Lee, Julia Button, Blake E. Dewey, Scott D. Newsome, Ellen M. Mowry, Kathryn C. Fitzgerald, Jerry L. Prince, Peter A. Calabresi, Shiv Saidha

Summary: This study investigated longitudinal changes in brain volumetric measures and retinal layer thicknesses following acute optic neuritis in people with multiple sclerosis. The results suggest that there is anterograde trans-synaptic degeneration after acute optic neuritis, which may have clinical relevance to visual outcomes.

ANNALS OF NEUROLOGY (2023)

Article Orthopedics

Tranexamic acid is not associated with decreased infection risk after primary shoulder arthroplasty: a cohort study of 9276 patients

Jacob Gorbaty, Priscilla H. Chan, Matthew D. McElvany, Heather A. Prentice, Edward H. Yian

Summary: This study aimed to determine whether the use of TXA reduces the risk of infection after primary elective shoulder arthroplasty. A retrospective cohort study of over 9000 patients found that the preoperative use of TXA was not associated with a decrease in the 5-year probability of revision for deep infection.

JOURNAL OF SHOULDER AND ELBOW SURGERY (2023)

Article Immunology

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study

Daniel J. Stieh, Dan H. Barouch, Christy Comeaux, Michal Sarnecki, Kathryn E. Stephenson, Stephen R. Walsh, Sheetal Sawant, Jack Heptinstall, Georgia D. Tomaras, James G. Kublin, M. Juliana McElrath, Kristen W. Cohen, Stephen C. De Rosa, Galit Alter, Guido Ferrari, David Montefiori, Philipp Mann, Steven Nijs, Katleen Callewaert, Paul A. Goepfert, Srilatha Edupuganti, Etienne Karita, Michael S. Seaman, Lawrence Corey, Lindsey R. Baden, Maria G. Pau, Hanneke Schuitemaker, Frank Tomaka

Summary: This study developed a cross-clade, globally effective HIV vaccine through clinical trials on healthy individuals with low risk for HIV infection. The findings showed that adding mosaic gp140 to the vaccine regimen increased and broadened the elicited immune response without compromising safety or clade C responses.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Orthopedics

Comparison of 90-Day Adverse Events Associated With Aspirin and Potent Anticoagulation Use for Venous Thromboembolism Prophylaxis: A Cohort Study of 72,288 Total Knee and 35,142 Total Hip Arthroplasty Patients

Gurpreet Singh, Heather A. Prentice, Benjamin A. Winston, Erik W. Kroger

Summary: This study compared the efficacy and safety of aspirin and potent anticoagulation agents in preventing VTE after TKA and THA. The results showed that aspirin was as effective as LMWH and warfarin in both TKA and THA, and it was also effective in higher-risk patients. However, the noninferiority of aspirin compared to factor Xa inhibitors has not been confirmed.

JOURNAL OF ARTHROPLASTY (2023)

Article Orthopedics

Prolonged Opioid Usage Following Hip Fracture Surgery in Opioid-Naive Older Patients

Kanu Okike, Richard N. Chang, Priscilla H. Chan, Elizabeth W. Paxton, Heather A. Prentice

Summary: This study investigated prolonged opioid usage after hip fracture in older individuals and found that the risk factors included younger age, female gender, smoking history, fracture fixation, and anxiety. Prolonged usage was less common among Asian patients and those with a history of dementia.

JOURNAL OF ARTHROPLASTY (2023)

Article Orthopedics

An Interrupted Time Series Analysis Measuring the Impact of Research and Education on Clinical Practice Decreasing Allograft Use in Young Patients Using a Registry to Track Outcomes

Gregory B. Maletis, Heather A. Prentice, Ronald W. B. Wyatt, Elizabeth W. Paxton, Tadashi T. Funahashi

Summary: We evaluated if allograft utilization for primary ACL reconstruction changed after implementing a program to reduce allograft use, and if revision rates changed after the intervention. Our study showed a decrease in allograft utilization and a decrease in ACL reconstruction revision rates following the intervention.

JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2023)

Article Immunology

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials

Christine B. Turley, LaKesha Tables, Trevon Fuller, Lisa J. Sanders, Hyman Scott, Amaran Moodley, Amanda Woodward Davis, Brett Leav, Jacqueline Miller, Kathryn Schoemaker, An Vandebosch, Jerald Sadoff, Wayne Woo, Iksung Cho, Lisa M. Dunkle, Sijia Li, Lars van der Laan, Peter B. Gilbert, Dean Follmann, Holly Jaynes, James G. Kublin, Lindsey R. Baden, Paul Goepfert, Karen Kotloff, Cynthia L. Gay, Ann R. Falsey, Hana M. El Sahly, Magdalena E. Sobieszczyk, Yunda Huang, Kathleen M. Neuzil, Lawrence Corey, Beatriz Grinsztejn, Glenda Gray, Nadine Rouphael, Alex Luedtke

Summary: This article reports on a cross-protocol analysis of four Phase 3 COVID-19 trials, analyzing placebo-controlled data. The analysis shows that the effectiveness of different vaccine platforms against symptomatic and severe COVID-19 is not influenced by baseline socio-demographic, clinical, or exposure characteristics. This supports the use of these vaccines as effective tools in reducing COVID-19.

VACCINE (2023)

Article Public, Environmental & Occupational Health

Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region

Shelly Karuna, Jorge Gallardo-Cartagena, Deborah Theodore, Portia Hunidzarira, Juan Montenegro-Idrogo, Jiani Hu, Megan Jones, Vicky Kim, Robert De La Grecca, Meg Trahey, Carissa Karg, Azwi Takalani, Laura Polakowski, Julia Hutter, Maurine D. Miner, Nathan Erdmann, Paul Goepfert, Rebone Maboa, Lawrence Corey, Katherine Gill, Shuying Sue Li

Summary: This global observational cohort study investigated the convalescent course of SARS-CoV-2 infection among adults in Africa, North America, and South America. The study found that the severity of infection, race, lung disease, and region were associated with the duration of post-COVID symptoms.

JOURNAL OF GLOBAL HEALTH (2023)

Article Immunology

Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

Nadine G. Rouphael, Angela R. Branche, David J. Diemert, Ann R. Falsey, Cecilia Losada, Lindsey R. Baden, Sharon E. Frey, Jennifer A. Whitaker, Susan J. Little, Satoshi Kamidani, Emmanuel B. Walter, Richard M. Novak, Richard Rupp, Lisa A. Jackson, Tara M. Babu, Angelica C. Kottkamp, Anne F. Luetkemeyer, Lilly C. Immergluck, Rachel M. Presti, Martin Backer, Patricia L. Winokur, Siham M. Mahgoub, Paul A. Goepfert, Dahlene N. Fusco, Robert L. Atmar, Christine M. Posavad, Antonia Netzl, Derek J. Smith, Kalyani Telu, Jinjian Mu, Lisa J. McQuarrie, Mat Makowski, Mamodikoe K. Makhene, Sonja Crandon, David C. Montefiori, Paul C. Roberts, John H. Beigel, Kuleni Abebe

Summary: A comparison was conducted on the serologic responses in adults between a single dose and a two-dose variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine). The findings indicate that a two-dose boosting regimen with a variant vaccine does not enhance the magnitude or durability of the serological responses compared to a single variant vaccine boost.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Biochemistry & Molecular Biology

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

Angela R. Branche, Nadine G. Rouphael, David J. Diemert, Ann R. Falsey, Cecilia Losada, Lindsey R. Baden, Sharon E. Frey, Jennifer A. Whitaker, Susan J. Little, Evan J. Anderson, Emmanuel B. Walter, Richard M. Novak, Richard Rupp, Lisa A. Jackson, Tara M. Babu, Angelica C. Kottkamp, Anne F. Luetkemeyer, Lilly C. Immergluck, Rachel M. Presti, Martin Baecker, Patricia L. Winokur, Siham M. Mahgoub, Paul A. Goepfert, Dahlene N. Fusco, Elissa Malkin, Jeffrey M. Bethony, Edward E. Walsh, Daniel S. Graciaa, Hady Samaha, Amy C. Sherman, Stephen R. Walsh, Getahun Abate, Zacharoula Oikonomopoulou, Hana M. El Sahly, Thomas C. S. Martin, Satoshi Kamidani, Michael J. Smith, Benjamin G. Ladner, Laura Porterfield, Maya Dunstan, Anna Wald, Tamia Davis, Robert L. Atmar, Mark J. Mulligan, Kirsten E. Lyke, Christine M. Posavad, Megan A. Meagher, David S. Stephens, Kathleen M. Neuzil, Kuleni Abebe, Heather Hill, Jim Albert, Kalyani Telu, Jinjian Mu, Teri C. Lewis, Lisa A. Giebeig, Amanda Eaton, Antonia Netzl, Samuel H. Wilks, Sina Tuereli, Mamodikoe Makhene, Sonja Crandon, David C. Montefiori, Mat Makowski, Derek J. Smith, Seema U. Nayak, Paul C. Roberts, John H. Beigel, COVAIL Study Grp

Summary: In this study, boosting with updated vaccines targeting SARS-CoV-2 variants provides broadly crossprotective neutralizing antibody responses without sacrificing immunity to the ancestral strain.

NATURE MEDICINE (2023)

Article Medicine, General & Internal

Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study

Kai Qin, Kazuhito Honjo, Scott Sherrill-Mix, Weimin Liu, Regina M. Stoltz, Allisa K. Oman, Lucinda A. Hall, Ran Li, Sarah Sterrett, Ellen R. Frederick, Jeffrey R. Lancaster, Mayur Narkhede, Amitkumar Mehta, Foluso J. Ogunsile, Rima B. Patel, Thomas J. Ketas, Victor M. Cruz M. Portillo, Albert Cupo, Benjamin M. Larimer, Anju Bansal, Paul A. Goepfert, Beatrice H. Hahn, Randall S. Davis

Summary: This study investigated the immune response of chronic lymphocytic leukemia (CLL) patients to the COVID-19 vaccine. The results showed that CLL patients had lower seroconversion rates and antibody titers compared to healthy individuals. The cellular immune response was also weaker in CLL patients. The study identified mRNA-1273 vaccine as more effective than BNT162b2 vaccine for CLL patients. Alternative vaccine regimens should be considered for CLL patients and other immunocompromised populations.

PLOS MEDICINE (2023)

Article Immunology

Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial

Mark A. Marzinke, Brett Hanscom, Zhe Wang, Steven A. Safren, Christina Psaros, Deborah Donnell, Paul A. Richardson, Philip Sullivan, Susan H. Eshleman, Andrea Jennings, Kailazarid Gomez Feliciano, Emilia Jalil, Carolina Coutinho, Nadir Cardozo, Bernardo Maia, Taimur Khan, Yashna Singh, Keren Middelkoop, Julie Franks, Javier Valencia, Naiymah Sanchez, Jonathan Lucas, James F. Rooney, Alex R. Rinehart, Susan Ford, Adeola Adeyeye, Myron S. Cohen, Marybeth McCauley, Raphael J. Landovitz, Beatriz Grinsztejn

Summary: This study characterizes the cohort of transgender women included in the HPTN 083 trial. The results show that transgender women were well represented in the trial and should continue to be prioritized in HIV prevention studies. Injectable cabotegravir is a safe and effective pre-exposure prophylaxis option for transgender women.

LANCET HIV (2023)

Article Surgery

Mesh-based inguinal hernia repairs in an integrated healthcare system and surgeon and hospital volume: a cohort study of 110,808 patients from over a decade

J. Spivak, P. H. Chan, H. A. Prentice, E. W. Paxton, E. R. Brill

Summary: The purpose of this study was to describe a cohort of patients who underwent inguinal hernia repair and evaluate the risk for postoperative events by surgeon and hospital volume within each surgical approach. The results showed that high-volume surgeons may reduce reoperation risk following laparoscopic inguinal hernia repair.

HERNIA (2023)

Article Surgery

Risk factors for reoperation following inguinal hernia repair: results from a cohort of patients from an integrated healthcare system

Cheryl L. Park, P. H. Chan, H. A. Prentice, K. Sucher, E. R. Brill, E. W. Paxton, B. Laxa

Summary: This study identified several risk factors associated with reoperation following inguinal hernia repair, including increasing age, female gender, increasing body mass index, White race, chronic pulmonary disease, diabetes, drug abuse, peripheral vascular disease, and bilateral procedures. These risk factors may be targeted for optimization protocols to reduce reoperation risk prior to elective inguinal hernia repair.

HERNIA (2023)

暂无数据